This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Teva faces claims in Germany, Netherlands over EU abuse of MS drug

By Lewis Crofts ( February 7, 2025, 10:10 GMT | Insight) -- Teva Pharmaceuticals is the target of private litigation in Germany and the Netherlands as it contests an antitrust fine over its handling of multiple sclerosis drug Copaxone that drew sanctions from the European Commission last year. The company was fined in October and last month filed an appeal at the EU courts. The private litigation has been stayed, the company said.Teva Pharmaceuticals is the target of private litigation in Germany and the Netherlands related to an antitrust abuse of its multiple sclerosis drug that drew sanctions from the European Commission last year....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections